In vitro studies revealed that Everolimus (RAD001) markedly reduces the clonogenic survival of bladder cancer cells and enhances radiotherapy efficacy by inhibiting downstream mTOR signaling, such as p-S6 phosphorylation, and regulating the cell cycle. Here, MTOR is linked to urinary bladder cancer.